Additional immune reactive program contained various genes associated with immune response and activation pathways such as antigen presentation (e.g., HLA-A, HLA-B, HLA-C, CD74, CTSS), interferon (IFN) signaling (e.g., IRF1, IFIH1, IFITM1, IFNAR1), chemokines (e.g., CCR2, CCR10) and tumor necrosis factor (TNF) signaling via NF-kB (e.g., TNFAIP3, NFKB1 and NFKB2) (Fig. 2C and Additional file 1: Table S2).Upregulation of the immune genes program was found in post-treated samples (Fig. 2D), suggesting therapy induced anti–myeloma immune response mediated by multiple pathways activation. This evidence concerns the gene IFNA1 and plasma cell myeloma.